RAPT Therapeutics Inc
RAPT58.020USD
0.0000.00%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
1.32BMarket Cap
LossP/E TTM
More Details of RAPT Therapeutics Inc Company
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
RAPT Therapeutics Inc Info
Ticker SymbolRAPT
Company nameRAPT Therapeutics Inc
IPO dateOct 31, 2019
CEOWong (Brian)
Number of employees68
Security typeOrdinary Share
Fiscal year-endOct 31
Address561 Eccles Ave
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16504899000
Websitehttps://rapt.com/
Ticker SymbolRAPT
IPO dateOct 31, 2019
CEOWong (Brian)
Company Executives of RAPT Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Rodney K. B. Young
Mr. Rodney K. B. Young
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
-100.00%
Ms. Linda Kozick
Ms. Linda Kozick
Independent Director
Independent Director
--
-100.00%
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Dr. Ashley Dombkowski, Ph.D.
Dr. Ashley Dombkowski, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Rodney K. B. Young
Mr. Rodney K. B. Young
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
-100.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Feb 19
Updated: Thu, Feb 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Medicxi Ventures (UK) LLP
9.65%
TCG Crossover Management, LLC
8.92%
Forbion Capital Partners
6.33%
OrbiMed Advisors, LLC
5.67%
RTW Investments L.P.
5.65%
Other
63.78%
Shareholders
Shareholders
Proportion
Medicxi Ventures (UK) LLP
9.65%
TCG Crossover Management, LLC
8.92%
Forbion Capital Partners
6.33%
OrbiMed Advisors, LLC
5.67%
RTW Investments L.P.
5.65%
Other
63.78%
Shareholder Types
Shareholders
Proportion
Hedge Fund
32.03%
Investment Advisor
26.01%
Private Equity
17.32%
Investment Advisor/Hedge Fund
17.05%
Venture Capital
16.62%
Research Firm
1.62%
Individual Investor
0.24%
Pension Fund
0.07%
Bank and Trust
0.06%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
290
18.77M
64.82%
+126.40K
2025Q3
290
16.78M
61.62%
-1.23M
2025Q2
295
16.40M
99.19%
-1.13M
2025Q1
309
29.14M
109.47%
+11.54M
2024Q4
309
140.52M
106.54%
+100.36M
2024Q3
304
31.22M
87.82%
-13.95M
2024Q2
305
33.18M
93.85%
-9.52M
2024Q1
295
33.76M
95.60%
-5.47M
2023Q4
282
36.46M
106.02%
-3.53M
2023Q3
281
36.40M
105.98%
-3.26M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Medicxi Ventures (UK) LLP
2.79M
10.08%
--
--
Sep 30, 2025
TCG Crossover Management, LLC
1.64M
5.9%
--
--
Sep 30, 2025
Forbion Capital Partners
1.83M
6.62%
+1.49M
+432.58%
Oct 23, 2025
OrbiMed Advisors, LLC
1.09M
3.92%
-555.29K
-33.82%
Sep 30, 2025
RTW Investments L.P.
1.47M
5.31%
--
--
Sep 30, 2025
Foresite Capital Management, LLC
1.56M
5.64%
--
--
Sep 30, 2025
Invus Public Equities Advisors, LLC
580.47K
2.09%
+580.47K
--
Sep 30, 2025
The Vanguard Group, Inc.
696.19K
2.51%
-183.86K
-20.89%
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Invesco Dorsey Wright SmallCap Momentum ETF
0.56%
Avantis US Small Cap Equity ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Schwab U.S. Broad Market ETF
0%
Blueprint Chesapeake Multi-Asset Trend ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Russell 3000 ETF
0%
Pacer WealthShield ETF
0%
T Rowe Price Small-Mid Cap ETF
0%
View more
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.56%
Avantis US Small Cap Equity ETF
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Schwab U.S. Broad Market ETF
Proportion0%
Blueprint Chesapeake Multi-Asset Trend ETF
Proportion0%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
Pacer WealthShield ETF
Proportion0%
T Rowe Price Small-Mid Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Jun 13, 2025
Merger
8→1
Date
Ex-dividend Date
Type
Ratio
Jun 13, 2025
Merger
8→1
